EIKN biotech catalysts & pipeline

Eikon expects additional results from the combination of EIK1005 with pembrolizumab to be available in the first half of 2027, with complete results for EIK1005 monotherapy available in the second half of 2027.

Source filing

EIK1003 — Clinical data readout

H2 2027

Eikon is currently enrolling an additional Cohort 1D evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy, for which initial results are expected in the second half of 2027.

Source filing

EIK1004 — Clinical data readout

H2 2027

Eikon plans to initiate a combination arm of EIK1004-001 evaluating EIK1004 in combination with docetaxel, with plans to report initial results from that combination arm in the second half of 2027.

Source filing

EIK1005 — Full data

H2 2027

Eikon expects additional results from the combination of EIK1005 with pembrolizumab to be available in the first half of 2027, with complete results for EIK1005 monotherapy available in the second half of 2027.

Source filing

EIK1001 — Conference presentation

Oct 26

Title: 2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results Date: Monday, October 26, 2026

Source filing

EIK1001 — Conference presentation

Oct 26

Eikon will present comprehensive updated data from TeLuRide-005 ( NCT06246110 ), an ongoing open-label Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology-appropriate chemotherapy for the treatment of patients with non–small cell lung cancer (NSCLC), on Monday, October 26 at the ESMO Congress 2026 in Madrid, Spain.

Source filing

Explore the free biotech catalyst calendar